Mice Model Market by Type (Conditioned/Surgically Modified Mice, Genetically Engineered Mice, Hybrid/Congenic Mice), Technology (CRISPR/CAS9, Embryonic Stem Cell Injection, Microinjection), Therapeutic Area, Application - Global Forecast 2024-2030

Mice Model Market by Type (Conditioned/Surgically Modified Mice, Genetically Engineered Mice, Hybrid/Congenic Mice), Technology (CRISPR/CAS9, Embryonic Stem Cell Injection, Microinjection), Therapeutic Area, Application - Global Forecast 2024-2030

The Mice Model Market size was estimated at USD 1.49 billion in 2023 and expected to reach USD 1.61 billion in 2024, at a CAGR 8.34% to reach USD 2.61 billion by 2030.

Mice models are laboratory mice (Mus musculus) used by scientists and researchers for biomedical research and studies related to genetic engineering, drug discovery, and therapeutic testing. These models are pivotal in mimicking human disease processes due to the genetic, biological, and behavioral similarities between humans and mice. Mice models enable the scientific community to understand disease mechanisms, assess drug efficacy, and explore potential treatments before they are tested in humans. The increasing demand for personalized medicine, the growing prevalence of various genetic disorders, and a surge in biomedical research involving cancer, cardiovascular diseases, and neurological disorders enhanced the usage of mice models. The rise in regulatory approvals for pharmaceutical drugs also necessitates extensive preclinical studies, further propelling the demand for mice models. Despite the significant growth, the mice model market faces several challenges, such as ethical concerns related to animal testing, the high cost of creating and maintaining genetically engineered mice models, and the complexity of reproducing human diseases in mice. However, the continual development of CRISPR/Cas9 gene-editing technology presents novel avenues for creating more accurate and diverse disease models. Additionally, the increasing investment in biomedical research and development by both public and private sectors worldwide offers a significant boost to the market.

Regional Insights

The mice model market is growing significantly in the Americas owing to continuous research activities by research organizations and pharmaceutical companies. Moreover, federal government support in terms of grants and investment for drug development and vaccine development has enhanced the scope of the mice model in the region. However, the rising genetic disease and neurological complications in European countries have increased the utilization of mouse models to understand age-related diseases. In addition, emerging clinical research institutes and favorable government initiatives drive market development in the EMEA region. The rising need for personalized medications, surging geriatric disease, increasing cases of immune disease, and growing prevalence of infectious disease boost the adoption of mice models across the Americas and Europe regions. On the other hand, the Asia-Pacific region witnesses significant growth prospects of the mice models market in the forecast period owing to growing research activities and government initiatives for clinical activities. APAC's increasing population and prevalence of chronic diseases underscore the need for extensive research, thereby propelling the adoption of mice models.

Market Insights

Market Dynamics

The market dynamics represent an ever-changing landscape of the Mice Model Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.

Market Drivers

Escalating use of mice models for drug testing and research of immune disease
Rising investments and grants coupled with surging pharmaceutical R&D activities

Market Restraints

High costs associated with development of mice models

Market Opportunities

Emerging implementation of AI and ML in mice modeling
Advent of CRISPR-Cas9 technology in mice modeling

Market Challenges

Stringent regulations and laws considering the ethical use of animals in research

Market Segmentation Analysis

Type: Growing significance of genetically engineered mice for evaluating gene therapy outcomes
Application: Rising adoption of mice models to explore therapeutic efficacy and safety profiles before clinical trials

Market Disruption Analysis

Porter’s Five Forces Analysis
Value Chain & Critical Path Analysis
Pricing Analysis
Technology Analysis
Patent Analysis
Trade Analysis
Regulatory Framework Analysis

FPNV Positioning Matrix

The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Mice Model Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Mice Model Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Recent Developments

Biocytogen Officially Launches RenMice Series

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. introduced the RenMice series. This innovative collection features independently developed mice, including fully human antibody and TCR mice, RenMab, RenLite, RenNano, RenTCR™, and RenTCR-mimic, each holding proprietary intellectual property rights. The name Ren, meaning human in Chinese, encapsulates the company's dedication to pushing the boundaries of novel therapeutic discovery and development for human health.

Introducing NeoMab: GemPharmatech's Innovative Antibody Gene Humanized Mouse Model

GemPharmatech has unveiled NeoMab, a full antibody gene humanized mouse model, culminating from four years of meticulous research and validation. Specifically tailored for the expanding needs of therapeutic antibody development in biotechnology and pharmaceutical sectors, NeoMab is engineered on the well-established BALB/c genetic foundation. This model masterfully combines the native mouse immune system's robustness with human-specific variable regions, thereby offering a potent tool for antibody discovery and research innovation.

A Mouse That Roars: Chinese Scientists Create The First Mammal With Fully Reprogrammed Genes

Chinese scientists have created its first fully functional mammal model. This new development marks a significant advancement in the field of biomedical research, which relies heavily on the use of mice as model organisms to simulate human physiology and diseases. The success of this experiment proves the feasibility of this cutting-edge technology, and also sets the stage for more sophisticated research in the years to come.

Strategy Analysis & Recommendation

The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Mice Model Market. This critical assessment involves a thorough analysis of the organization’s resources, capabilities, and overall performance to identify its core strengths and areas for improvement.

Key Company Profiles

The report delves into recent significant developments in the Mice Model Market, highlighting leading vendors and their innovative profiles. These include Applied StemCell, Inc., Aragen Life Sciences Ltd., Biocytogen Boston Corporation, Charles River Laboratories International, Inc., CompareNetworks, Inc., Creative Biolabs., Crown Bioscience by JSR Life Sciences, LLC, Cyagen US Inc. by PolyGene AG, Envigo by Inotiv, Inc., GenOway, Harbour BioMed, Horizon Discovery Ltd. by PerkinElmer, Inc., inGenious Targeting Laboratory, Inc., ITR Laboratories Canada, Janvier Labs, Marshall BioResources, MD Biosciences, Mirimus, Inc., Oncodesign, SA, Ozgene Pty Ltd., PhoenixBio Co., Ltd., Shanghai Model Organisms Center, Inc., Taconic Biosciences, Inc., The Jackson Laboratory, TransCure bioServices, Translational Drug Development, LLC, Transnetyx, Inc., Urosphere SAS, Vivo Bio Tech Ltd., and XenOPAT SL by Bellvitge Biomedical Research Institute.

Market Segmentation & Coverage

This research report categorizes the Mice Model Market to forecast the revenues and analyze trends in each of the following sub-markets:

Type
Conditioned/Surgically Modified Mice
Genetically Engineered Mice
Hybrid/Congenic Mice
Inbred Mice
Outbred Mice
Technology
CRISPR/CAS9
Embryonic Stem Cell Injection
Microinjection
Nuclear Transfer
Therapeutic Area
Cardiovascular Diseases
Immunology
Metabolic Diseases
Neurology
Oncology
Application
Drug Discovery & Development
Personalized Medicine
Research Application
Region
Americas
Argentina
Brazil
Canada
Mexico
United States
California
Florida
Illinois
New York
Ohio
Pennsylvania
Texas
Asia-Pacific
Australia
China
India
Indonesia
Japan
Malaysia
Philippines
Singapore
South Korea
Taiwan
Thailand
Vietnam
Europe, Middle East & Africa
Denmark
Egypt
Finland
France
Germany
Israel
Italy
Netherlands
Nigeria
Norway
Poland
Qatar
Russia
Saudi Arabia
South Africa
Spain
Sweden
Switzerland
Turkey
United Arab Emirates
United Kingdom

Please Note: PDF & Excel + Online Access - 1 Year